Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays

Bio-Rad Laboratories’ Q2 2026 earnings call cited 10% sequential revenue growth, with year-over-year pressure from softer academic research and cautious biopharma demand. Management reaffirmed full-year currency-neutral revenue guidance of -3% to +0.5% and expects ddPCR instrument revenue up 20% and $30m to $35m net annual savings by 2027.

BIODESIX INC (BDSX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bdsx-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Biodesix Announces Second Quarter 2026 Results and Highlights Delivered $26.9 million in revenue, representing 34% growth in Q2 2026; Achieved 82% gross margin in Q2 2026; Maintained FY 2026 Revenue Guidance of $108-114 milli

Bio-Rad Laboratories (BIO) said Q2 demand from academic and government customers stayed below historical levels, especially in the Americas, though NIH outlays are rising. It reported stabilization signs in biopharma, with China revenue down in the high teens and a ~$4M H2 headwind. Q2 non-GAAP EPS was $2.62. Gross margin was 53.1%. Bio-Rad reaffirmed 2026 guidance and announced restructuring with $30M-$35M annualized savings.

BIO-RAD LABORATORIES, INC. (BIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 bio-8k842026xex991.htm EX-99.1 Document Exhibit 99.1 Press Release Bio-Rad Reports Second -Quarter 2026 Financial Results HERCULES, Calif.—August 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnosti

Realty Income (NYSE: O) says it began investing in data centers in late 2023 via a build-to-suit JV with Digital Realty, buying an 80% stake in an up to 48 MW facility. It also formed a hyperscale JV with Cloud Capital, targeting up to $1.4B investment for a 45% stake. Realty Income raised 2024 AFFO guidance to $4.44-$4.45/share and investment outlook to $10B.

Bloomberg reported the US Army plans to buy at least $400 million of AeroVironment counter-drone laser systems, citing a person familiar with the deal. The order would include dozens of LOCUST units that use AI to detect and track small to medium drones and then engage them with a high-energy laser. AeroVironment’s stock rose about 8% on Friday.